1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

SPC Waiver Builds Momentum After EU Vote

 
• By Dave Wallace

Several EU-level endorsements for a proposed SPC manufacturing waiver – which would allow manufacturing within Europe during the SPC period for export, as well as stockpiling for ‘day one’ launch upon SPC expiry – have been applauded by the region’s off-patent industry. However, originators are doubling down on lobbying efforts against such changes.

EU parliament
Parliament endorses SPC waiver • Source: Shutterstock

A vote by the European Parliament’s international trade committee, INTA, endorsing a proposed waiver allowing manufacturing during the term of supplementary protection certificates (SPCs) has been applauded by off-patent industry association Medicines for Europe. It follows recognition by the EU’s competitiveness council as well as “constructive amendments” to the current SPC waiver proposal that were recently offered by the Parliament’s health committee.

Welcoming the trade committee vote, Medicines for Europe said that it had introduced “several important amendments to improve the original...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Glenmark Targets Revival Of Monroe Manufacturing Unit Following FDA Findings

 
• By Dean Rudge

Glenmark expects to restart US commercial production at its Monroe, North Carolina injectables plant soon, after a recent FDA inspection resulted in a Form 483 with five procedural GMP observations, but none related to data integrity.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

Celltrion Nears Deal For US Biologics Plant To Quell Tariff Concerns

 
• By Dean Rudge

Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By Dean Rudge

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

More from Business

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By Dave Wallace

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 
• By Urtė Fultinavičiūtė

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.